Novartis Ag (NVS) EPS (Weighted Average and Diluted) Growth (3y) (2012 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
76.98% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
318.57% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
44.22% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-52.54% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-14.16% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
26.25% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-21.46% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
6.98% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
-26.08% |
| Dec 31, 2024 |
28.45% |
| Jun 30, 2024 |
-21.36% |
| Dec 31, 2023 |
-67.85% |
| Sep 30, 2023 |
-27.55% |
| Jun 30, 2023 |
-76.33% |
| Mar 31, 2023 |
-11.29% |
| Mar 31, 2022 |
86.84% |
| Dec 31, 2021 |
390.40% |
| Sep 30, 2021 |
77.09% |
| Jun 30, 2021 |
508.02% |
| Mar 31, 2021 |
101.49% |
| Dec 31, 2020 |
106.73% |
| Sep 30, 2020 |
-1.57% |
| Jun 30, 2020 |
4.49% |
| Mar 31, 2020 |
-35.10% |
| Mar 31, 2019 |
-37.57% |
| Dec 31, 2018 |
-107.69% |
| Sep 30, 2018 |
-52.66% |
| Jun 30, 2018 |
7,871.71% |
| Mar 31, 2018 |
4,900.76% |
| Dec 31, 2017 |
8,812.43% |
| Sep 30, 2017 |
17,928.52% |
| Jun 30, 2017 |
27,409.14% |
| Mar 31, 2017 |
11,113.40% |
| Sep 30, 2016 |
12,254.50% |
| Jun 30, 2016 |
26,740.74% |
| Sep 30, 2015 |
5,683.75% |
| Jun 30, 2015 |
-27.69% |
| Mar 31, 2015 |
-0.16% |
| Dec 31, 2014 |
-41.67% |
| Sep 30, 2014 |
-36.63% |
| Jun 30, 2014 |
-31.33% |
| Mar 31, 2014 |
-3.74% |
| Sep 30, 2013 |
-14.42% |
| Jun 30, 2013 |
-27.78% |
| Sep 30, 2012 |
696.21% |
| Jun 30, 2012 |
562.21% |
| Mar 31, 2012 |
718.51% |
